An Open-Label, Multi-Center, Dose-Escalation, Phase 1 Study of the Safety, Tolerability,'BR'Pharmacodynamics, and Pharmacokinetics of RTA 408 in the Treatment of Patients with Advanced Solid Tumors

Trial Profile

An Open-Label, Multi-Center, Dose-Escalation, Phase 1 Study of the Safety, Tolerability,'BR'Pharmacodynamics, and Pharmacokinetics of RTA 408 in the Treatment of Patients with Advanced Solid Tumors

Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2014

At a glance

  • Drugs Omaveloxolone (Primary)
  • Indications Malignant melanoma; Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 05 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top